2022
Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer
Leone JP, Hassett MJ, Leone J, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Lin NU. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. Cancer 2022, 128: 3796-3803. PMID: 36069365, PMCID: PMC9826058, DOI: 10.1002/cncr.34448.Peer-Reviewed Original ResearchConceptsPathologic complete responseFive-year OSNeoadjuvant chemotherapyMale breast cancerBreast cancerTumor subtypesOverall survivalIndependent associationEfficacy of NACInitiation of NACHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2National Cancer DatabaseGrowth factor receptor 2Multivariable logistic regressionFemale breast cancerFactor receptor 2HR-/HER2Complete responseMedian timeMultivariable analysisKaplan-MeierCancer DatabaseReceptor 2Logistic regression
2021
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer
Janiszewska M, Stein S, Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop I, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer. JCI Insight 2021, 6: e147617. PMID: 33886505, PMCID: PMC8262355, DOI: 10.1172/jci.insight.147617.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesDNA Copy Number VariationsDrug Resistance, NeoplasmEpithelial CellsFemaleFibroblastsHumansMacrophagesMiddle AgedMutationNeoplasm TransplantationReceptor, ErbB-2TrastuzumabTumor MicroenvironmentVesicular Transport ProteinsConceptsBreast cancerTherapeutic resistanceHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Patient-derived xenograft modelsLymphatic vessel endothelial hyaluronan receptorHER2-targeted therapiesGrowth factor receptor 2Impact of tumorFibroblastic reticular cellsFactor receptor 2Tumor epithelial cellsIntratumor heterogeneityDivergent cellular phenotypesResistance-conferring mutationsClinical outcomesPIK3CA mutationsTreatment responseClinical challengeDifferent therapiesFrequency of cellsXenograft modelReceptor 2Stromal determinants
2018
Breast cancer‐specific survival by age: Worse outcomes for the oldest patients
Freedman RA, Keating NL, Lin NU, Winer EP, Vaz‐Luis I, Lii J, Exman P, Barry WT. Breast cancer‐specific survival by age: Worse outcomes for the oldest patients. Cancer 2018, 124: 2184-2191. PMID: 29499074, PMCID: PMC5935594, DOI: 10.1002/cncr.31308.Peer-Reviewed Original ResearchConceptsBreast cancer-specific deathCancer-specific deathTriple-negative diseaseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Breast cancer outcomesOlder patientsFactor receptor 2Breast cancerCancer outcomesReceptor 2Disease subtypesWorse breast cancer outcomesHR-positive diseaseCancer stage IEnd Results (SEER) dataAmerican Joint CommitteePopulation-based cohortStage of diseaseGray regression modelsAdjusted hazardClinical variablesDisease stageHigh risk
2016
Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Freedman R, Polley M, Dueck A, Hurria A, Muss H, Ruddy K, Hubbard J, Liu H, Rogak L, Basch E, Dakhil S, Huff J, Bajaj M, Wilkinson M, Al Baghadadi T, Benjamin S, Mowat R, Hudis C, Rugo H, Winer E. Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Journal Of Clinical Oncology 2016, 34: tps629-tps629. DOI: 10.1200/jco.2016.34.15_suppl.tps629.Peer-Reviewed Original Research
2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, MacDonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Research And Treatment 2013, 142: 405-414. PMID: 24197661, DOI: 10.1007/s10549-013-2754-0.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyDose-limiting toxicityObjective response rateHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Positive breast cancerCentral nervous diseasesBrain metastasesFactor receptor 2Brain radiotherapyBreast cancerReceptor 2CNS objective response rateBreast cancer brain metastasesHigher objective response rateCareful safety monitoringCancer brain metastasesGrade 3 rashPre-defined criteriaEligible patientsEvaluable patientsLapatinib 1000Pulmonary emboliDose escalationLong‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer 2013, 119: 3943-3951. PMID: 24037735, DOI: 10.1002/cncr.28284.Peer-Reviewed Original ResearchConceptsDistant disease-free survivalCongestive heart failureEarly breast cancerHuman epidermal growth factor receptor 2Breast cancerTrial ALong-term cardiac safetyEpidermal growth factor receptor 2Dose-dense doxorubicinDose-dense chemotherapyAnti-HER2 therapyDisease-free survivalPhase 2 trialGrowth factor receptor 2Long-term incidenceFactor receptor 2Previous hypertensionCumulative incidenceHeart failureAdditional patientsCardiac safetyLower riskReceptor 2PatientsTrial B.
2010
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer. Clinical Cancer Research 2010, 16: 4702-4710. PMID: 20858840, PMCID: PMC2948607, DOI: 10.1158/1078-0432.ccr-10-0939.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast cancerPARP inhibitorsClinical trialsAdvanced triple-negative breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2PARP inhibitionAdvanced breast cancerGrowth factor receptor 2Clinico-pathologic featuresPositive breast cancerNovel therapeutic classFactor receptor 2Mechanism of actionPreclinical rationalePreclinical modelsNovel agentsReceptor 2CancerTherapeutic classesPolymerase inhibitorsPolymerase inhibitionDNA repairInhibitors
2008
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. Journal Of Clinical Oncology 2008, 26: 1642-1649. PMID: 18375893, DOI: 10.1200/jco.2007.11.6699.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerWeekly paclitaxelResponse rateBreast cancerHER-2-positive patientsRandomized phase III trialHuman epidermal growth factor receptor 2End pointEpidermal growth factor receptor 2Grade 3 neuropathyPrimary end pointSecondary end pointsGrowth factor receptor 2Phase II trialPhase III trialsTreatment-limiting toxicityFactor receptor 2Paclitaxel scheduleII trialIII trialsOverall survivalPaclitaxel therapyPositive patientsWeekly dosingReceptor 2